Actinium Highlights Improved Survival with Iomab-B in TP53 P

Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in

Related Keywords

Texas , United States , San Antonio , American , Avinash Desai , International Blood Marrow Transplant Research , American Society For Transplantation , Actimaba National Cancer Institute , Marrow Transplant Research , Exchange Commission , Actinium Pharmaceuticals Inc , International Blood , Prnewswire Actinium Pharmaceuticals Inc , Cellular Therapy , American Society , Complete Remission , Chief Medical Officer , Iomabb Phase , Apamistamab Improves Outcomes , Targeted Myeloablative Radiation Using , Apamistamab Prior , Allogeneic Hematopoietic Cell Transplant , B Cell Acute Lymphoblastic Leukemia , Diffuse Largeb Cell , Tandem Meetingsi Transplantation , Cellular Therapy Meetings , Actinium Pharmaceuticals , National Cancer Institute , Region ,